Original Article

Activation of the IL-6/JAK/STAT3 signaling pathway in human middle ear cholesteatoma epithelium

Wei Liu1*, Shumin Xie1*, Xing Chen1, Xingwang Rao3, Hongmiao Ren1, Bing Hu1, Tuanfang Yin1, Yuyan Xiang2, Jihao Ren1

1Department of Otolaryngology Head and Neck Surgery, The Second Xiangya Hospital of Central South University, Changsha, China; 2Department of Human Anatomy, University of South China, Hengyang, China; 3Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. *Equal contributors.

Received December 3, 2013; Accepted December 20, 2013; Epub January 15, 2014; Published February 1, 2014

Abstract: Interleukin-6 (IL-6) is one of the most important cytokines which has been shown to play a critical role in the pathogenesis of cholesteatoma. In this study, we aimed to investigate the expression of interleukin-6 (IL-6) and phosphorylated signal transducer and activator of transcription 3 (p-STAT3) in middle ear cholesteatoma epithelium in an effort to determine the role of IL-6/JAK/STAT3 signaling pathway in the pathogenesis of cholesteatoma. Immunohistochemistry was used to examine the expression of IL-6 and p-STAT3 in 25 human middle ear cholesteatoma samples and 15 normal external auditory canal (EAC) epithelium specimens. We also analyzed the relation of IL-6 and p-STAT3 expression levels to the degree of bone destruction in cholesteatoma. We found that the expression of IL-6 and p-STAT3 were significantly higher in cholesteatoma epithelium than in normal EAC epithelium (p<0.05). In cholesteatoma epithelium, a significant positive association was observed between IL-6 and p-STAT3 expression (p<0.05). However, no significant relationships were observed between the degree of bone destruction and the levels of IL-6 and p-STAT3 expression (p>0.05). To conclude, our results support the concept that IL-6/JAK/STAT3 signaling pathway is active and may play an important role in the mechanisms of epithelial hyper-proliferation responsible for cholesteatoma.

Keywords: Cholesteatoma, IL-6, STAT3

Introduction

Cholesteatoma is a pathological condition associated with otitis media, accompanying hearing loss, facial paralysis, labyrinthine and brain abscess, and the recurrence after surgical treatment is very common. Cholesteatoma is morphologically characterized by epithelial cell proliferation and granulation tissue formation. Unfortunately, our understanding of the molecular mechanism underlying the pathogenesis of cholesteatoma is limited. Recently, many authors have demonstrated that cytokines and mediators secreted in the inflammatory responses may change the biochemical signaling pathways that mediate the pathogenesis of cholesteatoma [1-4].

Interleukin-6 (IL-6) is one of the most important cytokines which has been shown to play a critical role in the pathogenesis of cholesteatoma, such as epithelial hyper-proliferation and bone destruction. For example, increased IL-6 expression has been described in cholesteatoma tissues. Moreover, cholesteatoma keratinocytes showed higher production of IL-6 as compared with normal external auditory canal (EAC) skin. However, the exact mechanisms of IL-6 in the pathogenesis of cholesteatoma remain unknown. Interleukin-6 (IL-6) is a pleiotropic cytokine that plays an important role in a variety of cellular events including inflammatory reaction, immune response and cellular proliferation [4]. Signal transducer and activator of transcription 3 (STAT3) is a lipid kinase that controls cell growth, proliferation and survival, anabolic and autophagic activities and cytoskeletal organization [7], and is proved to have a major function in promoting cellular proliferation and inhibiting apoptosis in response to IL-6 [8]. Coupling with
the IL-6 receptor and gp130, IL-6 activates a Janus kinase (JAK)-dependent signaling cascade, mediating tyrosine phosphorylated STAT3 (p-STAT3). STAT3 signaling pathway has been a hot spot in the pathogenesis exploration for proliferative diseases nowadays, but it is rare studied in the genesis and development of cholesteatoma.

In this study, we hypothesized that the IL-6/JAK/STAT3 signaling pathway may be activated and involved in the pathogenesis of cholesteatoma. To investigate this, we determined the expression of IL-6 and p-STAT3 in cholesteatoma and normal EAC skin by immunohistochemical analysis. We also analyzed the relation of IL-6 and p-STAT3 expression levels to the degree of bone destruction in cholesteatoma.

Materials and methods

Materials

A series of 25 acquired cholesteatoma tissues was obtained during middle ear surgery between January 2010 and June 2010 at the Department of Otolaryngology, Head and Neck Surgery. Of these, 16 were males and 9 were females with a mean age of 35 years. Meanwhile, 15 normal EAC skin samples were obtained to be used as controls. Specimens for hematoxylin-eosin (HE) staining and immunohistochemistry were immediately fixed in 10% buffered formalin and embedded in paraffin.

Immunohistochemistry

The avidin-biotin complex method was performed on tissue sections (4 μm thick). Sections were heated at 60°C for 2 h, deparaffinized with xylene for 15 min and rehydrated in a graded ethanol series (100%, 95%, 80%, 70%). The tissue sections were washed in phosphate-buffered saline (PBS) and endogenous peroxidase was inactivated by incubating 3% hydrogen peroxide at room temperature for 10 min, followed by being washed with PBS. Then tissue sections were treated in a microwave oven using 10 mmol/L citrate buffer (PH 6.0) for 30 min. Subsequently, the sections were pre-incubated with non-immune goat blood serum for 10 min at room temperature and then were incubated overnight at 4°C with primary rabbit anti-p-STAT3 polyclonal antibody or anti-IL-6 monoclonal antibody. After rinsing 3 times with PBS, sections were incubated with the secondary biotinylated goat-anti-rabbit antibody for 15 min at room temperature. Then sections were incubated with streptavidin conjugated with horse radish peroxidase after washing in PBS. Freshly prepared 3-amino-9-ethylcarbazole was used as a substrate for peroxidase. Finally, the sections were counterstained with hematoxylin, dehydrated and mounted. For the negative controls, PBS was used to substitute primary antibody [2].

Evaluation of immunohistochemistry

All tissue sections were analyzed independently by two experienced pathologists who were blind to the clinical data of patients. Cells with uniform red granules were regarded as positive cells. Both the percentage of positive cells and the intensity of staining were considered [9]. The percentage of positive cells was graded and scored as 0 for negative staining, 1 for <30%, 2 for 30-60%, and 3 for >60% positive cells. Staining intensity was graded and scored as 0 for negative staining, 1 for light red, 2 for red, and 3 for dark red. The overall score for each specimen was obtained by multiplying the percentage score and the staining intensity score. The final results were recorded as negative (-) with an overall score of 0, weak positive (+) with an overall score of 1-2, moderate positive (++) if the overall score was 3-5, and strong positive (+++) if the overall score was 6-9.

Analysis of the relation of IL-6 and p-STAT3 expression levels to the degree of bone destruction

The degree of bone destruction was evaluated as follows: grade I - cases without any bone destruction or with mild erosion of one ossicle; grade II - cases with moderate destruction of all ossicles; grade III - cases with severe and widespread destruction including all ossicles, tegmen, external ear canal, bony facial canal, horizontal semicircular canal and inner ear.

Statistical analysis

Statistical analysis was performed by SPSS 15.0 software. Protein expression patterns and relationships between the protein expression levels and the degree of bone destruction were both analyzed with the Chi-square test. Spearman's rank correlation test was adopted.
IL-6/JAK/STAT3 in cholesteatoma

Figure 1. HE staining of human cholesteatoma (A) and normal EAC skin (B). (A) The keratin debris, matrix epithelium and perimatrix subepithelial tissue of cholesteatoma are seen. Original magnification: 100×. (B) The epithelium and subepithelial tissue of normal EAC skin are seen. Original magnification: 200×.

to analyze correlations between the expression of p-STAT3 and IL-6. A value of P<0.05 was considered statistically significant.

Ethics

The study was approved by the Ethics Committee of Central South University and informed consent was obtained from all of the patients.

Results

Histopathological findings

HE staining under light microscope showed that all 25 cholesteatoma specimens consisted of three parts: matrix, perimatrix and keratin debris (Figure 1A), confirming to the pathological criterion of diagnosis. Meanwhile, results of 15 normal EAC skin sections were also accorded with pathological diagnostic criterion (Figure 1B).

Immunohistochemistry

The expression of IL-6 in cholesteatoma was observed predominantly in the cytoplasm with light red or red staining and was localized in the basal and suprabasal layers of the epithelium (Figure 2A). Whereas in normal EAC skin epithelium, IL-6 expression was negative or weak positive (Figure 2B). The positive rate of IL-6 expression was 72% (18/25) in cholesteatoma epithelium compared to 20% (3/15) in normal EAC skin epithelium (Table 1, Figure 3). When compared with normal EAC skin epithelium, the positive rate of IL-6 expression in cholesteatoma epithelium was significantly increased (p=0.003).

In cholesteatoma epithelium, p-STAT3 expression was mainly observed in the cytoplasm and nucleus with red staining and was localized in the basal and suprabasal layers of the epithelium (Figure 2C). However, in normal EAC epithelium, p-STAT3 expression was barely detectable in the cytoplasm and nucleus (Figure 2D). The positive rate of p-STAT3 expression was 64% (16/25) in cholesteatoma epithelium and 26.67% (4/15) in normal EAC skin epithelium (Table 1). A significant difference was found in p-STAT3 expression between cholesteatoma epithelium and normal EAC skin epithelium (p=0.022).

Correlations between IL-6 and p-STAT3 in cholesteatoma epithelium

Among 16 cholesteatoma epithelium specimens with positive p-STAT3 expression, positive IL-6 expression was observed in 14 specimens; while among 18 cholesteatoma epi-
IL-6/JAK/STAT3 in cholesteatoma

Figure 2. Immunohistochemical staining of IL-6 (A, B) and p-STAT3 (C, D) in human cholesteatoma epithelium and normal EAC skin. (A) IL-6 expression in cholesteatoma was observed predominantly in the cytoplasm with red staining and was localized in the basal and suprabasal layers of the epithelium. Original magnification: 200×. (B) IL-6 expression in normal EAC skin was negative. Original magnification: 200×. (C) p-STAT3 expression in cholesteatoma was observed in the cytoplasm and nucleus with red staining and was localized in the basal and suprabasal layers of the epithelium. Original magnification: 200×. (D) p-STAT3 expression in normal EAC skin was negative. Original magnification: 200×.

thelium specimens with positive IL-6 expression, negative p-STAT3 expression was observed in 4 specimens. Using Spearman’s rank correlation test, a significant positive correlation was found between p-STAT3 and IL-6 in cholesteatoma epithelium (p=0.021) (Table 2).

Relations of IL-6 and p-STAT3 expression levels to the degree of bone destruction

According to operative findings, 7 patients had grade I bone destruction, 14 had grade II bone destruction, and 4 had grade III bone destruct-
IL-6/JAK/STAT3 in cholesteatoma

We then analyzed the relationships between the protein expression levels and the degree of bone destruction. However, no relationship was found between the degree of bone destruction and the expression levels of IL-6 (p=0.313) and p-STAT3 (p=0.512) (Table 3).

Discussion

IL-6 is a pro-inflammatory cytokine characterized as a potent activator of STAT3. They function cooperatively to promote cellular proliferation and inhibit apoptosis [10]. In this study, we focused on IL-6/JAK/STAT3 signaling pathway and studied its function in human cholesteatoma epithelium. As we expert, the significant presence of high IL-6 expression and p-STAT3 over-expression was observed in cholesteatoma epithelium. Consistent with our findings, previous studies also reported an increased expression of IL-6 and STAT3 in cholesteatoma epithelium [6, 11]. Furthermore, a significantly positive association was observed between IL-6 and p-STAT3 expression, namely, obviously increased p-STAT3 expression existed in cholesteatoma epithelium with IL-6 high expression, indicating the persistent activation of IL-6/JAK/STAT3 signaling in the hyperplasia of cholesteatoma epithelium. Similar results were obtained by Jiang GX et al. [12], they reported that IL-6 promoted STAT3 activation significantly at a posttranslational level in vitro and indicated that IL-6/STAT3 signaling was involved in human biliary epithelial cell migration and wound healing.

Via the binding to gp130, IL-6 mainly activates JAK/STAT signal pathway to mediate a variety of cellular functions [10, 12, 13]. Combination of IL-6 and IL-6 receptor can phosphorylate the tyrosine of gp130, and further activate JAK family members including JAK1, JAK2, and tyrosine kinase2 (Tyk2). Then, STAT3 is phosphorylated by the activated JAK and translocates into the nucleus to control the expression of substrates [14]. As shown in Table 1, significant difference in the expression of IL-6 was observed between cholesteatoma epithelium and normal EAC epithelium (P=0.003). Marenda SA et al. [16] also found a positive rate of 100% and 25% for IL-6 expression in cholesteatoma epithelium and normal EAC skin, respectively, with a statistical significance. Moreover, they demonstrated a strong correlation between the expression level of IL-6 and ossicula auditus destruction, indicating a vital role of IL-6 in the bone destruction of cholesteatoma. All these results emphasize on the importance of IL-6 in the pathogenesis and development of cholesteatoma.

Table 1. Protein expression of IL-6 and p-STAT3 in cholesteatoma epithelium and normal EAC skin

<table>
<thead>
<tr>
<th>Cases</th>
<th>IL-6</th>
<th>p-STAT3</th>
<th>χ²</th>
<th>p</th>
<th>χ²</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chol</td>
<td>25</td>
<td>18</td>
<td>7</td>
<td>10.165</td>
<td>0.003</td>
<td>16</td>
</tr>
<tr>
<td>EAC</td>
<td>15</td>
<td>3</td>
<td>12</td>
<td></td>
<td></td>
<td>4</td>
</tr>
</tbody>
</table>

Chol = cholesteatoma; EAC = normal EAC skin.

Table 2. Correlations between IL-6 and p-STAT3 in cholesteatoma epithelium

<table>
<thead>
<tr>
<th>IL-6</th>
<th>p-STAT3</th>
<th>r</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>+</td>
<td>14</td>
<td>4</td>
<td>0.460</td>
</tr>
<tr>
<td>-</td>
<td>2</td>
<td>5</td>
<td></td>
</tr>
</tbody>
</table>

Figure 3. The positive rate of IL-6 and p-STAT3 in cholesteatoma epithelium and normal EAC skin: the positive rate of IL-6 expression was 72% (18/25) in cholesteatoma epithelium compared to 20% (3/15) in normal EAC skin epithelium.
be an essential factor in cell over-proliferation. As shown in Table 1, significant difference in the expression of p-STAT3 was observed between cholesteatoma epithelium and normal EAC epithelium (P=0.022). Scanty research on the STAT3 expression in cholesteatoma has been carried out. David R et al. [17] detected the expression of STAT3 in cholesteatoma tissues and EAC skin, and discovered an obviously increased expression of p-STAT3 in cholesteatoma tissues as compared to normal EAC skin, indicating that the elevated expression of p-STAT3 promoted the genesis of cholesteatoma. The IL-6/JAK/STAT3 signaling pathway associates with various benign and malignant proliferative diseases. Recently, Liu ML et al. [18] demonstrated that IL-6/JAK/STAT3 signaling pathway prevented the genesis of breast cancer through inhibiting the Growth Regulation by Estrogen in Breast cancer (GREB1). da Silva CG et al. [19] also reported that liver regeneration was mediated by IL-6/JAK/STAT3 proliferative signaling. Our results are consistent with findings above and propose that IL-6/JAK/STAT3 signaling pathway is active in cholesteatoma epithelium and may represent a novel target for intratympanic drug therapies. In recent years, inhibitors of the IL-6/JAK/STAT3 signaling have emerged as a promising cancer treatment option. For instance, siRNA-STAT3 therapy was demonstrated effective in ovarian cancer [20], and suppressor of cytokine signaling treatment was also proved to be active in blocking the IL-6/JAK/STAT3 signaling in glioblastoma cells [21], such as JAK inhibitor (AG490) [22]. Meanwhile, the curcumin also has been proved to block small cell lung cancer cells migration, invasion, angiogenesis, and neoplasia through the IL-6/JAK/STAT3 pathway [23]. These strategies shed light on a new trend to cure tumors as well as benign proliferative diseases such as cholesteatoma.

Bone destruction is an essential characteristic in cholesteatoma. IL-6 is thought to be linked in the underlying pathology of bone destruction associated with cholesteatoma. Kuczkowski J et al [24] demonstrated the existence of a strong positive correlation between the increased expression of IL-6 in cholesteatoma tissues and the degree of bone destruction, and Nason R et al [25] revealed that the inhibition of IL-6 blocked the osteoclastogenesis which facilitating bone destruction in chronic otitis. However, in our study, no relationship was found between the degree of bone destruction and the expression levels of IL-6 and p-STAT3. This observation suggests that there may be pathways other than the IL-6/JAK/STAT3 signaling cascade that contribute to bone destruction in cholesteatoma.

In conclusion, increased protein expression of IL-6 and p-STAT3 was proved to exist in cholesteatoma epithelium. Furthermore, significantly positive correlation between IL-6 and p-STAT3 expression was confirmed. The increased protein expression of IL-6 and p-STAT3 and their association in cholesteatoma epithelium suggest that the activation of IL-6/JAK/STAT3 signaling pathway may be involved in cholesteatoma epithelial hyper-proliferation. We suggest that anti-IL-6/JAK/STAT3 pathway therapies will function as potent anti-proliferative agents in the cholesteatoma.

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Jihao Ren, Department of Otolaryngology Head and Neck Surgery, The Second Xiangya Hospital of Central South University, Changsha, China. Tel: 86-13875837130; E-mail: jihao5114@163.com

References

[3] Caliman e Gurgel JD, Pereira SB, Alves AL, Riheiro FQ. Hyperproliferation markers in ear ca-
IL-6/JAK/STAT3 in cholesteatoma


